Polyp Biopsy Market is expected to grow with a healthy CAGR of 6.2% during the forecast period and reach USD 1,624.1 Million by 2025. Polyps are caused due to abnormal cell growth and are mostly benign. However, if they are left untreated, they could turn cancerous. Conclusively, there is a need to diagnose polyp to avoid cancer. For doing the same, biopsy is a major diagnostic procedure. In this procedure, a sample of tissue is removed from the polyp and is analyzed under the microscope.
Rising incidences of polyps, growing geriatric populations, and increasing prevalence of colorectal cancer are projected to drive the market growth. Moreover, technological advancements related to biopsy is expected to fuel market growth. On the other hand, uncertain regulatory issues and biopsy-related risk of infections are expected to restrict the market growth during the forecast period.
The global polyp biopsy market has been segmented into type, distribution channel, end user, and region.
The global market, based on type, has been segmented into colonoscopy, colposcopy-directed biopsy, esophagogastroduodenoscopy, and laryngoscopy.
The global market, by distribution channel, has been divided into online sales channels and retail pharmacies.
The global market, by end user, has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.
Cardinal Health, Inc., Angiotech, Carefusion Corporation, C.R. Bard, Inc., Hologic, Inc., INRAD Inc., Devicor Medical Products Inc., Olympus, and DTR Medica are some of the key players operating in the global polyp biopsy market.
Global Polyp Biopsy Market, by Type
Global Polyp Biopsy Market, by Distribution Channel
Global Polyp Biopsy Market, by End User